BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.18.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220929T140000
DTEND;TZID=Europe/Brussels:20220929T150000
DTSTAMP:20220922T103100Z
CREATED:20220830T122553Z
LAST-MODIFIED:20220922T103100Z
UID:5064-1664460000-1664463600@www.europabio.org
SUMMARY:European Biotech Week 2022: At the cutting edge of biotechnology for cardiovascular diseases: A World Heart Day special edition webinar
DESCRIPTION:Healthcare Biotechnology has the potential to transform how healthcare is delivered to patients\, both in terms of innovative treatments\, but also via use of innovative prevention\, screening\, and testing measures. \n\n\n\nDuring this webinar\, which marks World Heart Day\, speakers will discuss how biomarker testing for genetically inherited risk factors for cardiovascular diseases is opening up new frontiers in healthcare\, and saving lives across the world. \n\n\n\nFeaturing speakers from the patient community\, research and academia\, and industry\, the conversation will also address the need to translate guidelines into practice\, and will end with an interactive Q&A. \n\n\n\nSpeakers: \n\n\n\nMarius Geanta\, Trustee and the Chair of the Policy Advisory Committee\, FH EuropeLena Lymperopoulou\, Global Policy Head Therapeutic Area Cardiovascular\, NovartisFlorian Kronenberg\, Full Professor and Head of the Institute of Genetic Epidemiology\, Medical University of InnsbruckJamie Wilkinson\, Healthcare Biotechnology Director\, EuropaBio\n\n\n\n\nREGISTER NOW
URL:https://www.europabio.org/event/european-biotech-week-2022-hc/
CATEGORIES:Biotech Week,EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Europabio-HC.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220927T140000
DTEND;TZID=Europe/Brussels:20220927T150000
DTSTAMP:20220914T134233Z
CREATED:20220830T105859Z
LAST-MODIFIED:20220914T134233Z
UID:5054-1664287200-1664290800@www.europabio.org
SUMMARY:European Biotech Week 2022: Innovative technologies in the EU green transition – spotlight on industrial biotechnology
DESCRIPTION:Industrial Biotechnology-derived products offer significant potential for contributing to overcoming many EU socio-economic and environmental challenges. It is not a new sector. On the contrary\, for thousands of years the power of microbes has been harnessed in food production and beverages. In the past century\, the applications for IB have expanded greatly with IB now providing living microorganisms and fermentation products that are used in sectors as diverse as food and feed\, agriculture\, detergents\, paper and pulp\, textiles\, fuels\, bioenergy\, and specialty chemicals. \n\n\n\nResearch and innovation are key drivers to accelerate the green transition. Indeed\, the EU Green Deal notes that “New technologies\, sustainable solutions and disruptive innovation are critical to achieve the objectives of the European Green Deal”. In this context\, a range of solutions will be needed. Alternatives to fossil-based products\, improved resource efficiency of industrial processes\, innovative food and feed are all targets where industrial biotechnology and bioeconomy innovation can deliver. \n\n\n\nThis webinar will discuss innovative solutions that can contribute towards the green transition\, with a focus on industrial biotechnology. It will zoom in on products of IB and their benefits and challenges\, also linking to the EU GMO regulatory framework and recent developments on new genomic techniques. \n\n\n\nSpeakers: \n\n\n\nMarc Leclerc\, Senior Regulatory Affairs Advisor\, NovozymesRachel Melnick\, Senior Scientific Program Manager\, Agriculture & Food Systems InstituteHans Genee\, Co-Founder and CSO\, Biosyntia\n\n\n\n\nREGISTER NOW
URL:https://www.europabio.org/event/european-biotech-week-2022-ib/
CATEGORIES:Biotech Week,EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Europabio-IB.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220926T140000
DTEND;TZID=Europe/Brussels:20220926T151500
DTSTAMP:20220923T072206Z
CREATED:20220830T121819Z
LAST-MODIFIED:20220923T072206Z
UID:5060-1664200800-1664205300@www.europabio.org
SUMMARY:European Biotech Week 2022: Biotechnology for society\, sustainability and economies – transformative science for a changing world
DESCRIPTION:The 2022 European Biotech Week from EuropaBio opens with a look at how biotechnology is at the centre of Europe’s transformation to a healthy\, sustainable and competitive economy and society. \n\n\n\nJoin our Board Members from across Europe’s biotechnology spectrum to learn about biotech in action and its benefits in our every day lives\, as well as how it supports employment\, economic development and Europe’s place in the world. \n\n\n\nSpeakers: \n\n\n\nPatricia Malarkey\, Global Chief Innovation Officer\, DSMStefan Buchholz\, Senior VP R&D Nutrition and Care\, EvonikTom Bols\, Head of Government Affairs and Patient Advocacy\, PTC TherapeuticsAnnemeik Verkamman\, Managing Director\, HollandBio\n\n\n\n\nREGISTER NOW
URL:https://www.europabio.org/event/european-biotech-week-2022-biotechnology-for-society-sustainability-and-economies-transformative-science-for-a-changing-world/
CATEGORIES:Biotech Week,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Events-Template-600-×-200px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220602T150000
DTEND;TZID=Europe/Brussels:20220602T161500
DTSTAMP:20220517T120255Z
CREATED:20220510T072627Z
LAST-MODIFIED:20220517T120255Z
UID:4513-1654182000-1654186500@www.europabio.org
SUMMARY:Rare Conversations 2022!
DESCRIPTION:Managing uncertainties in rare disease innovation\n\n\n\n\n\nJoins us for the new episode of Rare Conversations 2022! \n\n\n\nThe second episode of Rare Conversations 2022 will build on the previous Conversation about game-changing opportunities in rare disease R&D. In the first episode\, different experts convened on the existence of opportunities in rare diseases\, that still face obstacles that need to be addressed. This event is meant to discuss and propose solutions on: “Managing uncertainties in rare disease innovation”
URL:https://www.europabio.org/event/rare-conversations-2022-2/
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20211213T140000
DTEND;TZID=Europe/Brussels:20211213T150000
DTSTAMP:20211216T093602Z
CREATED:20211116T143909Z
LAST-MODIFIED:20211216T093602Z
UID:3429-1639404000-1639407600@www.europabio.org
SUMMARY:EuropaBio 25th Anniversary | mRNA: A voyage of discovery and celebration
DESCRIPTION:The existence of messenger(m) RNA was hypothesized early in the days of DNA breakthroughs in the 1960s\, and research from the 1990s started to reveal its potential as a therapeutic tool. \n\n\n\nmRNA became a household name in 2020 and 2021 as arguably the most important global breakthrough of recent years\, with its ability to create a specific proteins underpinning vaccine development in response to Covid-19.EuropaBio is delighted to host the final event of its 25th Anniversary programme with a focus on the story of mRNA. Its first steps into commercial development\, challenges to bring a vaccine to millions of people and life beyond Covid – the destination for mRNA in oncology and other significant health applications. \n\n\n\nWe bring together protagonists from across the spectrum\, including:• Ingmar Hoerr\, CureVac Founder and holder of the first patents associated with mRNA• Stephen Lockhart\, Head of EU/AP Vaccines Clinical R&D at Pfizer• Dhaval Patel\, Senior Manager\, Manufacturing & Technology\, Catalent Biologic
URL:https://www.europabio.org/event/europabio-25th-anniversary-mrna-a-voyage-of-discovery-and-celebration/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/11/Event-Banners-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20211130T140000
DTEND;TZID=Europe/Brussels:20211130T151500
DTSTAMP:20211119T105146Z
CREATED:20211103T141708Z
LAST-MODIFIED:20211119T105146Z
UID:3401-1638280800-1638285300@www.europabio.org
SUMMARY:EFIB 2021 | Vienna Statement Launch
DESCRIPTION:The ‘EFIB 2021 Vienna Statement’ marked the launch of an annual call to action from EuropaBio members\, with policy asks and actions critical in the short term for Europe’s delivery of a bioeconomy. \n\n\n\nDeveloped through 2021 and published at EFIB in Vienna\, the statement includes:• Next generation Europe: An urgent call to action• Industrial biotechnology: Proving its value to society\, environment and economy• The clock is ticking for European climate and competitive ambitions• Time is now – EFIB Vienna Statement requests for modernisation of regulation and policy\, Education and awareness and financing innovation \n\n\n\nModerator: \n\n\n\n• Dr Claire Skentelbery\, Director General\, EuropaBio \n\n\n\nSpeakers: \n\n\n\n• Stefan Buchholz\, Senior Vice President R&D Nutrition & Care\, Evonik \n\n\n\n• Elke Duwenig\,  Senior Biotechnology Expert Regulatory / Public & Government Affairs\, Nutrition & Health\, BASF \n\n\n\n• Jim Philp\, Science and Technology Analyst\, OECD \n\n\n\n• Video message by Simone Schmiedtbauer\, Member of the European Parliament\, Group of the European People’s Party\, Austria \n• Video message by Virginijus Sinkevičius\, European Commissioner for Environment\, Oceans and Fisheries \n\n\n\nWe invite you now to join us for the wider launch of the EFIB Vienna Statement – to set the challenge for Europe and discuss what this means for policy\, regulation\, investment and innovation. \n\n\n\nJoin us on 30 November at 14:00 CET and be part of the conversation in the 12 months until the next EFIB conference in Vilnius\, Lithuania\, October 2022. \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/efib-2021-vienna-statement-launch/
CATEGORIES:EFIB,EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/11/Event-Banners-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20211025T130000
DTEND;TZID=Europe/Brussels:20211025T141500
DTSTAMP:20211008T103436Z
CREATED:20210916T104948Z
LAST-MODIFIED:20211008T103436Z
UID:3115-1635166800-1635171300@www.europabio.org
SUMMARY:EuropaBio 25th Anniversary | Healthy planet\, Healthy people
DESCRIPTION:At the time of the 25th Anniversary of EuropaBio\, we would like to look to the future and the green transition that will shape healthcare for us all. \n\n\n\nThis open webinar aims at kicking off the discussion on pathway for green transition in the biopharmaceutical ecosystem. This biopharmaceutical ecosystem has a complex and resource intensive profile\, from research\, to manufacture through to use and disposal of highly regulated therapeutics. \n\n\n\nChange is Now\, with companies investing in long term product and process design for carbon neutrality and circularity.  Join us to hear from pharma\, sustainable pharmaceutical engineering\, policy makers\, consumers and the European Commission on the priorities\, actions and outcomes to ensure that healthy people go hand in hand with a healthy planet. \n\n\n\nModerator:  \n\n\n\nDr Claire Skentelbery\, Director General\, EuropaBio\n\n\n\nSpeakers:   \n\n\n\nCarmen Laplaza\, Head of Unit\, Health Innovations and Ecosystems\, DG Research and Innovation\n\n\n\nMontserrat Montaner\, Chief Sustainability Officer\, Novartis\n\n\n\nJutta Paulus\, Member of the European Parliament\, Group of the Greens\, Germany\n\n\n\nDr Wouter De Soete\, Manager Centre of Excellence in Sustainable Pharmaceutical Engineering & Manufacturing\, University of Ghent\n\n\n\nKristin Schreiber\, Director\, Directorate Ecosystems: Chemicals\, Food\, Retail\, Health\, DG Grow\, European Commission\n\n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/europabio-25th-anniversary-healthy-planet-healthy-people/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/09/Event-Banners-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20211019T110000
DTEND;TZID=Europe/Brussels:20211019T123000
DTSTAMP:20211013T123534Z
CREATED:20210929T082422Z
LAST-MODIFIED:20211013T123534Z
UID:3221-1634641200-1634646600@www.europabio.org
SUMMARY:EuropaBio Patient Bio-Forum | European Reference Networks: challenges\, achievements and opportunities
DESCRIPTION:EuropaBio\, the European Association for Bioindustries\, is proud to continue our platform for engaging patient and industry alike on pertinent healthcare debates: the Patient Bio-Forum. In this edition the focus will be on the impact of European Reference Networks (ERNs). \n\n\n\nWith an aim to facilitate discussion between patients and medical professionals across the EU\, ERNs tackle rare disease head on. Creating a pooled\, virtually accessible network of experts\, ERNs demonstrate the power of collaboration in diagnosis complex and rare diseases. With the first ERNs having started in 2017\, we anticipate a periodic evaluation during 2022/23. Similarly\, this year the Commission have undertaken an evaluation of the Cross-border Healthcare Directive which establishes the legal basis of ERNs. \n\n\n\nAgainst a backdrop of societal change\, the EuropaBio Patient Bio-Forum convenes this October with a panel of experts representing patient\, industry\, EU and Member State perspectives on the challenges\, achievements and opportunities the ERNs present. \n\n\n\n\n\n\n\nAGENDA \n\n\n\nWelcome and introduction (5 mins) \n\n\n\nNicola Bedlington (Moderator)\n\n\n\nPanel Discussion (45 mins) \n\n\n\nIngunn Westerheim\, President\, OIFE – Osteogenesis Imperfecta Federation Europe;Dr. Birute Tumienė\, clinical geneticist at the Centre for Medical Genetics and the Coordinator for Competence Centres in Vilnius University Hospital Santaros Klinikos\, ERN Board Member on behald of LithuaniaDr. Jose A. Valverde\, Policy Officer\, Unit B.3 – European Reference Networks and Digital Health\, DG SANTE\, European Commission;Assoc. Prof. Dr Till Voigtländer\, Department of Neuropathology and Neurochemistry University of Vienna\, Eurordis Black Pearl Awardee 2019Dirk Vander Mijnsbrugge\, Vice President Medical Affairs Lead Rare Diseases International Developed Markets\, Pfizer\n\n\n\nBiobreak/Slido Poll (5 mins) \n\n\n\nModerated Q&A (35 mins) \n\n\n\nFrom the audience\, submitted via chat function.\n\n\n\nClosing remarks
URL:https://www.europabio.org/event/europabio-patient-bio-forum-european-research-networks-challenges-achievements-and-opportunities/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/10/Event-Banners-28.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20211005T100000
DTEND;TZID=Europe/Brussels:20211007T190000
DTSTAMP:20210526T082935Z
CREATED:20210127T070638Z
LAST-MODIFIED:20210526T082935Z
UID:820-1633428000-1633633200@www.europabio.org
SUMMARY:European Forum for Industrial Biotechnology & the Bioeconomy (EFIB)
DESCRIPTION:Save the date for this 14th edition!EFIB is the market leading annual event in Europe for Industrial Biotechnology and the Bioeconomy. Visit the dedicated website to secure your place today. \n\n\n\n\n\nhttps://efibforum.com/
URL:https://www.europabio.org/event/european-forum-for-industrial-biotechnology-the-bioeconomy-efib/
LOCATION:Vienna (Austria)\, Vienna\, Austria
CATEGORIES:EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-EFIB.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210927T080000
DTEND;TZID=Europe/Brussels:20211003T080000
DTSTAMP:20210610T122254Z
CREATED:20210128T134240Z
LAST-MODIFIED:20210610T122254Z
UID:948-1632729600-1633248000@www.europabio.org
SUMMARY:European Biotech Week 2021
DESCRIPTION:The European Biotech Week celebrates biotechnology\, an innovative and vibrant sector launched by the discovery of the DNA molecule back in 1953. The first European Biotech Week that took place in 2013 marked the 60th anniversary of this pivotal moment in history. \n \n 
URL:https://www.europabio.org/event/european-biotech-week-2021/
CATEGORIES:EuropaBio,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/European-Biotech-Week-Event-Banner-.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210921T143000
DTEND;TZID=Europe/Brussels:20210921T153000
DTSTAMP:20210922T093101Z
CREATED:20210831T112430Z
LAST-MODIFIED:20210922T093101Z
UID:3028-1632234600-1632238200@www.europabio.org
SUMMARY:EFIB Pre-event webinar
DESCRIPTION:Sustainability in industrial biotech innovations: life cycle assessment and beyond \n\n\n\nSponsored by DSM\n\n\n\n \n\n\n\n\n\nGet ready for EFIB 2021 by attending the kick-off webinar “Sustainability in Industrial biotech innovations: Life Cycle Assessment and beyond”\, which will take place on Tuesday 21 September 2021 from 14.30 – 15.30 CET. \n\n\n\nSustainability is the drive and purpose behind most industrial biotech innovations. But how to incorporate it in the innovation process? How to assess it\, measure it\, and use it for decision making? During this webinar we will explore: \n\n\n\n• How well-established tools like Life Cycle Assessment are being used in industrial biotech innovations \n\n\n\n• What are novel tools and methodologies relevant for the sustainability assessment of industrial biotech \n\n\n\n• How corporates\, start-ups and academia use these tools in their innovation process \n\n\n\nThis kick-off webinar by EuropaBio is co-hosted by Planet B.io\, the open innovation hub for industrial biotechnology\, located at the Biotech Campus Delft in The Netherlands. \n\n\n\nModerator:  \n\n\n\n •  Maria Cuellar-Soares | S&T Officer\, Planet B.io \n\n\n\nSpeakers: \n\n\n\n •  Ulla Létinois | Senior Scientist\, Sustainable Chemistry\, DSM \n\n\n\n •  Yang Xiang | Senior Corporate LCA Expert\, DSM \n\n\n\n •  Cristina Prat | Co-founder\, FUL Foods \n\n\n\n •  John Posada | Assistant Professor in Biotechnology and Society\, TU Delft \n\n\n\n\nSlides\n\n\n\n\nParticipation for this webinar is free of charge\, but registration is required. \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/efib-pre-event-webinar/
CATEGORIES:EFIB
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/08/Event-Banners.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210907T160000
DTEND;TZID=Europe/Brussels:20210907T170000
DTSTAMP:20210903T072658Z
CREATED:20210715T095059Z
LAST-MODIFIED:20210903T072658Z
UID:2936-1631030400-1631034000@www.europabio.org
SUMMARY:Treatment without borders: the EU case for equitable patient access to advanced therapies
DESCRIPTION:The EU Pharmaceutical Strategy is looking to improve patients’ access to therapies for challenging and rare conditions. The EU legislation on cross-border healthcare is an important instrument to ensure patient access to the best available care. There is an urgent need to revise this legislation to enable EU patients to access novel advanced therapies and medicines for rare diseases when these are not available in their home country. \n\n\n\nEuropaBio’s Advanced Therapies Series continues with a virtual discussion on avenues for enhancing the access of EU patients to novel biotechnology-derived treatments on September 7\, 2021\, from 16h00 to 17h00 CET. \n\n\n\nA patient who is also actively engaged in patient advocacy will explain the value of advanced therapies for rare disease patients and the key challenges they encounter when accessing treatments outside their home countries. \n\n\n\nA panel of EU\, national\, and industry representatives will attempt to put forward solutions for securing equitable access to both specialised centres and to treatment for all EU patients in need. Among others\, they will seek to advise on how to tackle the following challenges: some treatment centres being less interested to treat cross-border patients\, the need for experience and expertise in rare diseases\, approval process and time for cross-border treatment\, lack of knowledge or experience of healthcare providers in requesting reimbursement for cross-border treatments\, difficulties in approving advanced therapy applications if not reimbursed in the home country\, etc. \n\n\n\nModerator \n\n\n\nBernard Grimm\, Healthcare Biotech Director\, EuropaBio \n\n\n\nSpeakers  \n\n\n\nJana Popova\, Executive Committee Member of the European Alliance of Neuromuscular Disorders Associations & EUPATI Patient Engagement Training Coordinator \n\n\n\nBrieuc Van Damme\, Director-General Healthcare\, RIZIV-INAMI \n\n\n\nMartin Dorazil\, Deputy Head of Unit\, DG Health\, European Commission \n\n\n\nDirk Vander Mijnsbrugge\, Vice President Medical Affairs Lead Rare Diseases International Developed Markets\, Pfizer \n\n\n\nIrina Grossenbacher\, Region Europe Patient Access Director\, Novartis Rare Diseases \n\n\n\nTomislav Sokol\, Member of the European Parliament\, EPP\, Croatia
URL:https://www.europabio.org/event/treatment-without-borders-the-eu-case-for-equitable-patient-access-to-advanced-therapies/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/07/NL-Size-28.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210630T121500
DTEND;TZID=Europe/Brussels:20210630T134500
DTSTAMP:20210611T110808Z
CREATED:20210609T145626Z
LAST-MODIFIED:20210611T110808Z
UID:2648-1625055300-1625060700@www.europabio.org
SUMMARY:Changing Global Ambitions for Biotechnology Innovation: Implications and Drivers for Europe
DESCRIPTION: \nEuropaBio hosts a member-only discussion session looking at ambitions for innovation and business in China\, and how this impacts both the EU and US. We are delighted to welcome McKinsey’s China office to the meeting\, where they will present an inside look at changing Chinese ambitions for industrial growth from innovation.\n \nMember discussion then focuses on how Europe can deliver its own ambitions in a world where changes beyond its borders will influence success\, and how it needs to develop a strong and realistic economic vision for technology from companies and governments.\n \nEuropaBio looks forward to an interesting cross-sector debate amongst Members on the long-term future of Europe as a global competitor and economic performer within the technology space\, within profound economic changes world-wide.\n \nAll members are eligible to attend and should contact EuropaBio (m.cilia@europabio.org) if they have not yet received an invitation.
URL:https://www.europabio.org/event/changing-global-ambitions-for-biotechnology-innovation-implications-and-drivers-for-europ/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/06/Event-Banners-25.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210603T140000
DTEND;TZID=Europe/Brussels:20210603T150000
DTSTAMP:20210602T083815Z
CREATED:20210315T132511Z
LAST-MODIFIED:20210602T083815Z
UID:1616-1622728800-1622732400@www.europabio.org
SUMMARY:EU Healthcare Biotech Policy Priorities for SMEs
DESCRIPTION:Join the EuropaBio Healthcare Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies. With the ongoing revision of the basic pharmaceutical legislation and of regulations for medicines for rare and paediatric diseases\, SMEs should be planning how they build and grow their businesses\, whether within the EU or outside. \n\n\n\nAbout the EuropaBio SME Platform \n\n\n\nThe SME platform is a community of SMEs across all sectors in Europe\, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders. \n\n\n\n  \n\n\n\n\nREGISTER HERE\n\n\n\n\n\n\n\n\n 
URL:https://www.europabio.org/event/eu-healthcare-biotech-policy-priorities-for-smes/
CATEGORIES:EuropaBio,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-9-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210527T130000
DTEND;TZID=Europe/Brussels:20210527T143000
DTSTAMP:20210528T100244Z
CREATED:20210511T134921Z
LAST-MODIFIED:20210528T100244Z
UID:2445-1622120400-1622125800@www.europabio.org
SUMMARY:EFIB 2021 Kick-Off Webinar - How to accelerate biotech innovation for a sustainable future
DESCRIPTION:Get ready for EFIB 2021 by joining our launch webinar “How to accelerate biotech innovation for a sustainable future”. \n\n\n\n EuropaBio is pleased to announce this kick-off webinar\, co-hosted by DSM and Planet B.io\, both located at the Biotech Campus Delft. The webinar will feature industry\, start-up\, and financing perspectives on the European biotechnology innovation ecosystem.  \n\n\n\nIt will provide insights on recent developments in the field\, discuss cooperation in the field and have an outlook on what to expect at EFIB 2021 in Vienna this year.  \n\n\n\nSpeakers:\n\n\n\n– Claire Skentelbery – General Director\, EuropaBio– Cindy Gerhardt – Managing Director\, Planet-B.io at the Biotech Campus Delft– Rob van der Meij – Partner\, Capricorn Partners– Amadeus Driando Ahnan-Winarno – Co-Founder & Head of Technology\, Better Nature \nYou can watch the video recording here\, or download the speakers’ presentations here. \n\n\n\n\n\n\n\n\n\n\nREGISTER HERE\n\n\n\n\n\n\n\n\n\n\n 
URL:https://www.europabio.org/event/efib-2021-kick-off-webinar-how-to-accelerate-biotech-innovation-for-a-sustainable-future/
CATEGORIES:EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2021/05/Event-Banners-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210520T140000
DTEND;TZID=Europe/Brussels:20210520T150000
DTSTAMP:20210517T090546Z
CREATED:20210421T071455Z
LAST-MODIFIED:20210517T090546Z
UID:2157-1621519200-1621522800@www.europabio.org
SUMMARY:Then and Now – Delivering a Successful Therapeutic to Patients
DESCRIPTION:In today’s whirlwind of diagnostics\, vaccines and therapeutics\, we take a step back and look at how the world of development and manufacturing of biologics has evolved over the last 25 years\, bringing together EuropaBio Members and 25th Anniversary Sponsor\, Catalent.We look back at changing experience from the last quarter of a century in the pathway to patients\, plus how the latest advanced technologies translate into effective pre-clinical and clinical development and manufacturing. Hear expert presentations from EuropaBio Members and Catalent Biologics\, before a detailed Q&A session with the audience on all aspects of developing a successful biologic in 2021. \n\n\n\nAspects to be discussed include: \n\n\n\nWhat trends are driving growth in the pharma industry\, and how are next generation therapies addressing previously unmet needs?As advanced technologies travel through the pipeline\, how are pharma companies\, CDMOs and other partners able meet their complex and novel requirements?In a global world\, how do you embrace and integrate skills and capacity from multiple sites\, often in different continents?As complex\, advanced medicines become reality\, how do you work with regulators from the earliest stages of pre-clinical development to enable a smooth pathway to clinic and market?\n\n\n\nFEATURED SPEAKERBehzad Mahdavi\, Ph.D.​Vice President of Open Innovation\, Biologics\, Cell and Gene Therapy \n\n\n\nMartine Lewi\,​Scientific Director\, Janssen R&D/Clinical Innovation \n\n\n\n \n\n\n\nWith over 20 years’ experience in developing and implementing impactful growth strategies in the biopharmaceutical industries\, Dr. Mahdavi joined Catalent in 2020 after a 13-year career at Lonza\, where he held the role of Vice President Strategic Innovation & Alliances\, and various board-level positions at other innovative companies. Prior to joining Lonza\, he was Chief Executive Officer of SAM Electron Technologies\, a venture capital-backed company in the life sciences field. He holds a doctorate in chemistry from the University of Sherbrooke\, Canada\, and also has a master’s in business administration from the University of Quebec in Montreal. \n\n\n\nJoin this webinar co-organised by Catalent and EuropaBio in the framework of EuropaBio 25th Anniversary and take part to the celebrations!  \n\n\n\n \n\n\n\n \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/then-and-now-delivering-a-successful-therapeutic-to-patients/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/04/Catalent-Webinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210518T103000
DTEND;TZID=Europe/Brussels:20210518T143000
DTSTAMP:20210427T094258Z
CREATED:20210324T082247Z
LAST-MODIFIED:20210427T094258Z
UID:1606-1621333800-1621348200@www.europabio.org
SUMMARY:EuropaBio Patient BioForum: Advancing patient access to innovative treatments
DESCRIPTION:2021 is set to be another landmark year in the area of health. It is hoped to not only relieve the burden of the COVID-19 pandemic on EU patients and healthcare systems\, but also let the health community advance the great number of other priorities there are. In the EU\, 2021 is set to give a start to the implementation of the European Health Union and the related objectives of the new EU Pharmaceutical Strategy. Among these\, the EU health community is looking to improve patients’ access to therapies for challenging and rare conditions. \n\n\n\nThis meeting of EuropaBio’s Patient BioForum will discuss avenues for enhancing the access of EU patients to novel biotechnology-derived treatments in two sessions: \n\n\n\nMorning session – 10:30-12:00 CET\n\n\n\nPharmaceutical Strategy implementation for continued innovation and delivery in the area of rare and paediatric diseases. \n\n\n\nThe European Commission is discussing on the calibration of incentives for investing in the development of medicines for rare and paediatric diseases both with Member States and stakeholders. We invite the BioForum members to exchange proposals for informing this important debate on several key points\, such as criteria for defining unmet need and incentivising innovation in such areas\, etc. \n\n\n\nAfternoon session – 13:00-14:30 CET\n\n\n\nImproving patient access across borders \n\n\n\nThe EU Directive on cross-border healthcare is an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases. Well-functioning EU cross-border healthcare legislation can ensure patients have access to specialised treatments and novel therapies when these are not available in their home country. \n\n\n\nThe exchange between guest speakers and BioForum members is aimed to result in the post-meeting release of policy recommendations for how patient access can be advanced in the EU in the context of its new Pharmaceutical Strategy. \n\n\n\nWe very much look forward to your active participation on 18 May 2021.  \n\n\n\n \n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/europabio-patient-bioforum-advancing-patient-access-to-innovative-treatments/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210511T120000
DTEND;TZID=Europe/Brussels:20210511T130000
DTSTAMP:20210506T121206Z
CREATED:20210312T082225Z
LAST-MODIFIED:20210506T121206Z
UID:1571-1620734400-1620738000@www.europabio.org
SUMMARY:Taking health up a gear: value of advanced therapies
DESCRIPTION:Advanced therapies have ground-breaking therapeutic potential\, particularly in disease areas where there is an unmet medical need and available therapeutic options are absent or inadequate. These therapies can bring the possibility of a cure to life-threatening conditions with a one-off treatment\, thereby changing the paradigm of providing health and care to patients suffering serious\, rare or complex diseases. \n\n\n\nA breakthrough innovator in the area of rare diseases will explain the cutting-edge science behind gene therapies\, why they are considered so transformative\, and what promise they hold to addressing unmet patient needs. \n\n\n\nA leading developer of the most innovative cancer treatments – CAR-T cell-based therapies will explain the changing paradigm of providing health for cancer patients and how innovation will help achieve the objectives of Europe’s Beating Cancer Plan. \n\n\n\nThe webinar will also engage policy makers reflecting live on how EU policies can truly harness the ground-breaking potential of advanced therapies. \n\n\n\nSpeakers \n\n\n\nSara Cerdas MEP\, BECA \n\n\n\nDick Sundh\, Head of ACE (Australia\, Canada & Europe) at Kite Pharma\, a Gilead Company  \n\n\n\nDirk Vander Mijnsbrugge\, Vice President Medical Affairs Lead Rare Diseases International Developed Markets at Pfizer \n\n\n\nSimone Boselli\, Public Affairs Director at EURORDIS  \n\n\n\n \n\n\n\nAbout EuropaBio Advanced Therapies Series: \n\n\n\nThe EuropaBio Advanced Therapies series of events\, interviews\, and publications will engage policymakers\, regulators\, patients and their representatives\, developers\, and all relevant stakeholders to discuss how innovation in gene- and cell-based medicine can bring a transformative value for patients. \n\n\n\nThroughout 2021\, we invite you to join us on a journey of exploring the tremendous potential of advanced therapies by discussing the new treatment paradigms\, the future of research and development in this fast-moving space of bio-science\, as well as debating recommendations for improving the access of patients to these ground-breaking treatments and supporting advanced manufacturing\, to name a few. \n\n\n\nVIRTUAL EVENT \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/taking-health-medicine-up-a-gear-value-of-advanced-therapies/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-10.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210510T150000
DTEND;TZID=Europe/Brussels:20210510T180000
DTSTAMP:20210511T074409Z
CREATED:20210316T153010Z
LAST-MODIFIED:20210511T074409Z
UID:1593-1620658800-1620669600@www.europabio.org
SUMMARY:Building on biotechnology: From vaccines to economic growth for Europe
DESCRIPTION:EuropaBio National Associations Council\n\n\n\nSummit 2021 – Portugal \n\n\n\n \n\n\n\n\n\n\n\n\n\nEuropaBio’s National Associations Council (NAC) is a platform that brings together all EuropaBio’s National Associations and helps to ensure coordination of EuropaBio actions throughout Europe. The NAC represents biotechnology priorities across Europe’s Member and partner countries\, working together to build long term economic and societal benefit from biotechnology across sectors. \n\n\n\nIn 2021\, the NAC is proud to host its first Summit focussed on priorities for commercial biotechnology development\, delivering the Industrial Strategy within national and European ecosystems. \n\n\n\nThe NAC summit on May 10 will address how we learn from the COVID-19 response\, to enable full societal and economic benefit from biotechnology in the future across sectors. Rapid technology development pathways\, including partnering\, investment and approvals\, created in response to the pandemic have created new\, faster routes to market. Although this was a unique scale and speed for vaccine development\, it shows that biotech can perform quickly and strongly to address unmet issues in healthcare and sustainable development\, creating a solution and also supporting economic recovery across Europe. \n\n\n\nThe EuropaBio NAC Summit is held during the Portuguese Presidency of the Council of EU and organized in collaboration with P-BIO. The outcomes from the Summit will include a EuropaBio NAC Position on building economic pathways from biotech post-Covid with the role of aligned and ambitious national policies and actions. \n\n\n\n \n\n\n\nAgenda\n\n\n\n15:00: Welcome – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n15:05: Opening remarks – Manuel Heitor\, Minister of Science\, Technology and Higher Education\, Portugal \n\n\n\n15:15: A European ambition in a competitive global landscape. \n\n\n\nWhere biotech and economic ambitions sit within European and global strategies – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n \n\n\n\n15:30: Session 1 – A new biotechnology ecosystem in Europe \n\n\n\n\nCompanies active in the current response to Covid-19 share how they have built vital collaborations across the biotech-pharma spectrum to deliver breakthrough vaccine technologies to patients at unprecedented speed\, plus how they envision future potential. \n\n\n\n15:30: Economic development driven by Biotech – the Portugal perspective: David Malta\, Founding CEO\, LiMM Therapeutics \n\n\n\n15:45: Developing bio-manufacturing partnerships – Elke Grooten\, Head of EU Relations\, Novartis \n\n\n\n16:00: Pharma-SME collaboration: from innovation to patient\, a global journey – Sinan Atlig\, Regional President IDM\, Vaccines Pfizer \n\n\n\n16:15: Break \n\n\n\n\n16:30: Session 2 – Looking to the future – speed and strength from biotech \n\n\n\nSMEs driving next generation biotechnology present the pathway and challenges to success and highlight what Europe needs to achieve.  EuropaBio National Associations will then discuss the critical framework needed to build further from national and European ecosystem advances from Covid\, accelerating biotech contribution to Europe’s economic development. \n\n\n\nSME drivers \n\n\n\n16:30: The future of vaccines – Bruno Santos\, Co-Founder and CEO\, IMMUNETHEP \n\n\n\n16:40: Reaching all patients for immunity – Kim Kjøller\, CEO\, UNION Therapeutics \n\n\n\nBuilding European strengths \n\n\n\n16:50: Discussion Panel – Associations from across Europe plus audience contributions \n\n\n\nModerator: Claire Skentelbery \n\n\n\nPanellists:  \n\n\n\n– Agne Vaitkeviciene\, Executive Director\, Lithuanian Biotechnology Association \n\n\n\n– Chloe Evans\, Market Research Manager & International Relations\, France Biotech \n\n\n\n– Simão Soares\, President\, P-BIO \n\n\n\n– Hanne Mette Dyrlie Kristensen\, CEO\, The Life Science Cluster (Norway) \n\n\n\n18:00: Summary and Close \n\n\n\nVIRTUAL EVENT \n\n\n\n\nREGISTER HERE\n\n\n\n\nWho should attend? \n\n\n\nThe EuropaBio NAC Summit is open and free of charge.  You should attend if you are active within the development of biotechnology ecosystems at national or European levels\, either as a technology stakeholder (academic or industrial) or a facilitator of technology maturation to market and patients (associations\, tech transfer\, investors\, policy makers…). The event will have a strong discussion element and all participants can be actively involved. The event will also develop preparatory statements for delegate feedback plus post-event discussion on the planned NAC Position. \n\n\n\nDownload below the speakers’ presentations: \n\n\n\nEuropaBio-NAC-Summit-10-May-2021-Slides-FINAL-PDFDownload
URL:https://www.europabio.org/event/building-on-biotechnology-from-vaccines-to-economic-growth-for-europe/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210422T140000
DTEND;TZID=Europe/Brussels:20210422T150000
DTSTAMP:20210409T131755Z
CREATED:20210315T132400Z
LAST-MODIFIED:20210409T131755Z
UID:1588-1619100000-1619103600@www.europabio.org
SUMMARY:EU Industrial Biotech Policy Priorities for SMEs
DESCRIPTION:Join the EuropaBio Industrial Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies.  With the Green Deal\, Industrial Strategy\, Circular Economy and many more\, SMEs can take advantage of changes and opportunities to plan and grow their business. \n\n\n\nAbout the EuropaBio SME Platform \n\n\n\nThe SME platform is a community of SMEs across all sectors in Europe\, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders. \n\n\n\n \n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/eu-industrial-biotech-policy-priorities-for-smes/
CATEGORIES:EuropaBio,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/SME-April-22-Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210415T130000
DTEND;TZID=Europe/Brussels:20210415T143000
DTSTAMP:20210318T105028Z
CREATED:20210316T094808Z
LAST-MODIFIED:20210318T105028Z
UID:1575-1618491600-1618497000@www.europabio.org
SUMMARY:An EU Vision for Life Science and Biotechnology for a Healthy and Sustainable EU
DESCRIPTION:With the ambitious target to cut greenhouse gas emissions by 55% compared to 1990 levels by 2030 and the EU Green Deal\, the EU has set clear goals to transform the bloc´s economy making it more sustainable while supporting the EU recovery. \n\n\n\nLife sciences and biotechnology remain critical key-enabling technologies for the economy\, generating GDP of over €34.5 billion\, employing 223\,000 people directly in the EU and generating a trade surplus of €22 billion in 2018.  Moreover\, the CO2 mitigation potential of industrial biotech is estimated between 1-2.5 billion tonnes of CO2 equivalent per year by 2030. \n\n\n\nThe Danish life science and biotechnology contributed to the local economy with over €14 billion export of goods and employing around 48\,000 jobs in 2019. Given the importance of this sector for the Danish economy\, the government is working on a new political strategy for the life science sector to succeed the sector’s growth plan implemented in March 2018. \n\n\n\nThe current COVID-19 pandemic has highlighted the need to employ a holistic and strategic approach and exploit synergies among various EU policies\, such as in the areas of research and innovation\, industry and health. Furthermore\, it showed us that the speed at which technologies develop requires that legislation is constantly up-to-date and able to embrace new sustainable innovation. Investing in the transition to a new sustainable economy requires modernised legislation that can support the green transition in the Member States and support the advancement of the EU life science and biotechnology to ensure they continue their main purpose to support the European Union’s ambitious agenda for healthy people and healthy planet. \n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/an-eu-vision-for-life-science-and-biotechnology-for-a-healthy-and-sustainable-eu/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210304T140000
DTEND;TZID=Europe/Brussels:20210304T153000
DTSTAMP:20210225T120052Z
CREATED:20210211T123919Z
LAST-MODIFIED:20210225T120052Z
UID:1355-1614866400-1614871800@www.europabio.org
SUMMARY:Measuring the Economic Footprint of the Biotechnology Industry in Europe
DESCRIPTION:Landscape and Positions for Economic Development: Industry and policy discussions to deliver biotechnology in Europe. \n\n\n\n\n\nEuropean GDP benefitted by €38.5 bn in 2018\, in the recent study from EuropaBio ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe’.  The study looked at the economic impact of the biotechnology industry within the (then) 28 European member states\, in terms of gross value added (GVA)\, employment and trade.  Including spill over effects\, that number rises to €78.7bn.  The direct contribution adds up to about 1.5% of total industrial GVA within the countries assessed\, supported by 223\,000 direct jobs rising to over 700\,000 with associated employment. \n\n\n\nVery few other sectors enhance quality of life\, knowledge\, innovation\, productivity\, andenvironmental protection as biotechnology does.  \n\n\n\nJoin EuropaBio on March 4 to find out more about the the economic footprint of biotechnology in Europe and be part of the discussion on its role in future economic recovery and delivering healthy people and planet.
URL:https://www.europabio.org/event/measuring-the-economic-footprint-of-the-biotechnology-industry-in-europe-landscape-and-positions-for-development/
CATEGORIES:EuropaBio,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2021/02/WebEx-Event-Banner-WifOR.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210223T110000
DTEND;TZID=Europe/Brussels:20210223T123000
DTSTAMP:20210225T111812Z
CREATED:20210203T204218Z
LAST-MODIFIED:20210225T111812Z
UID:1135-1614078000-1614083400@www.europabio.org
SUMMARY:#EUIndustryWeek2021: The next Industrial Revolution is a Bio Revolution
DESCRIPTION:Global challenges like COVID-19 and climate change require a range of solutions\, including those coming from innovative biotechnology. Life sciences and biotechnology is a key industrial sector which can play a transformative role in securing the EU’s competitive edge in health and sustainability.From new treatments for rare diseases to bio-based products\, biotechnology can revolutionize our approach to global challenges\, paving the way for an industrial revolution driven by the life sciences. \n\n\n\nJoin EuropaBio for presentations and discussion around the key issues where biotechnology is making a difference and how the scientific and business landscape will enable it in the future.Our panel will discuss the innovation potential of industrial and healthcare biotechnology for long term and future EU competitiveness\, including biotech SMEs as a critical part of the EU life sciences ecosystem\, and the need for a strategic approach for investment and innovation.Confirmed speakers: \n\n\n\nDr Marcus Remmers\, CTO\, Royal DSMMr Geoffrey Pot\, VP operations\, Takeda & bio.be ChairmanProf Isabel Rocha\, Pro-Rector of Nova University of LisbonDr Armin Spök\, TU Graz\, CHIC H2020 Project\n\n\n\nThis webinar is hosted by EuropaBio under the umbrella of the EU Industry Days and will be moderated by Dr Claire Skentelbery (Director-General\, EuropaBio).You can download below the speakers’ presentations: \n\n\n\nEU-Industry-Days-EuropaBio-Event-Armin-Spoek-PresentationDownload\n\n\n\nEU-Industry-Days-EuropaBio-Event-Geoffrey-Pot-PresentationDownload\n\n\n\nEU-Industry-Days-EuropaBio-Event-Isabel-Rocha-PresentationDownload\n\n\n\nEU-Industry-Days-EuropaBio-Event-Marcus-Remmers-PresentationDownload
URL:https://www.europabio.org/event/euindustryweek2021-the-next-industrial-revolution-is-a-bio-revolution/
LOCATION:VIRTUAL\, Avenue des Arts 53\, Brussels\, 1000\, Belgium
CATEGORIES:EuropaBio,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-EU-Ind.-Week-Ebio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210218T113000
DTEND;TZID=Europe/Brussels:20210218T130000
DTSTAMP:20210212T163254Z
CREATED:20210127T062632Z
LAST-MODIFIED:20210212T163254Z
UID:720-1613647800-1613653200@www.europabio.org
SUMMARY:EuropaBio National Associations Council: Brexit Impact for UK and Europe (Member-only webinar)
DESCRIPTION:As part of the EuropaBio National Associations Council\, this meeting kick starts a long term Brexit monitoring Group within EuropaBio which will support members to understand and manage Brexit changes and for the National Associations Council to identify priority topics for joint communications.
URL:https://www.europabio.org/event/brexit-impact-monitoring-members-only/
CATEGORIES:EuropaBio,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/02/Event-Banner-Brexit-NAC.png
END:VEVENT
END:VCALENDAR